PPARG and neoplasm: Our findings suggest that synthetic agonists may demonstrate more significant therapeutic benefits in cancer-prone individuals at high risk of developing cancer prior to a tipping point that leads to the irreversible repression of PPARγ and the development of a supportive tumor microenvironment.